HCC and Beyond: Expanding the Evidence and Potential for TACE
Impressions on current guidelines and the BCLC update, applications for TACE outside of HCC, the next-generation chemoembolization platforms, addressing patient questions, and expanding the reach of interventional oncology.
With William S. Rilling, MD, FSIR, and Teik Choon See, MBBCh, BAO, FRCS, FRCR, FBIR